UNSPSC 51372314: Mirfentanil

This classification denotes an opioid receptor agonist with the molecular formula C22H24N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q2U943H24P, chemically known as N-[1-(2-phenylethyl)piperidin-4-yl]-N-pyrazin-2-ylfuran-2-carboxamide but generally known as mirfentanil, which bears US NIH Compound Identifier 60698. European Medicines Agency schedules mirfentanil its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08988MIG. Most nations schedule mirfentanil under HS 29349990 and SITC 51579.

As of Q4 2014, MIRFENTANIL remains the US FDA Preferred Term for this commodity. SMILES: C1CN(CCC1N(C2=NC=CN=C2)C(=O)C3=CC=CO3)CCC4=CC=CC=C4.

UNSPSC 51372314 Mirfentanil is a Commodity code that nominally references a specific opioid pharmaceutical product, but recent state and local procurement activity under this code does not focus on mirfentanil itself. Instead, the code appears to capture a broader range of pharmaceutical procurement, including naloxone, generic multi-source drugs, and over-the-counter products acquired by health departments, state health and human services agencies, and cooperative purchasing alliances to support community health, pharmacy benefit programs, and medication-assisted treatment initiatives. Issuing bodies include county health departments, state health agencies, and multistate cooperative purchasing vehicles such as MMCAP. The pharmaceutical procurement under this code spans naloxone acquisition for opioid overdose response, generic pharmaceutical supply contracts serving state and local health systems, and exploratory procurement for direct-to-manufacturer prescription programs designed to optimize cost and distribution efficiency outside traditional pharmacy benefit manager channels.

Recent activity concentrates in the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries and electronic bid submission through the county e-Procurement Portal. The Minnesota Department of Administration, on behalf of the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring compliance with cGMP and the Drug Supply Chain Security Act and distribution through three authorized wholesalers. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription program capabilities, signaling early-stage procurement planning. The mismatch between the nominal code (mirfentanil) and the actual procurement scope suggests the code may be misapplied or serves as a catch-all for pharmaceutical acquisitions in state and local health systems.